Leslie Trigg Sells 3,361 Shares of Outset Medical (NASDAQ:OM) Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 3,361 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $3.35, for a total value of $11,259.35. Following the transaction, the chief executive officer directly owned 102,342 shares in the company, valued at approximately $342,845.70. This represents a 3.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Leslie Trigg also recently made the following trade(s):

• On Wednesday, January 21st, Leslie Trigg sold 2,120 shares of Outset Medical stock. The stock was sold at an average price of $5.05, for a total value of $10,706.00.
• On Tuesday, January 20th, Leslie Trigg sold 11,794 shares of Outset Medical stock. The shares were sold at an average price of $5.12, for a total transaction of $60,385.28.
• On Wednesday, January 7th, Leslie Trigg sold 1,795 shares of Outset Medical stock. The stock was sold at an average price of $4.27, for a total value of $7,664.65.

Outset Medical Trading Up 1.7%

NASDAQ OM traded up $0.06 on Thursday, reaching $3.53. The company had a trading volume of 201,581 shares, compared to its average volume of 359,322. The stock has a market cap of $64.63 million, a price-to-earnings ratio of -0.52 and a beta of 2.08. The stock’s 50 day moving average is $4.34 and its 200-day moving average is $9.06. The company has a quick ratio of 5.77, a current ratio of 6.67 and a debt-to-equity ratio of 0.76. Outset Medical, Inc. has a 52 week low of $3.10 and a 52 week high of $21.98.

Hedge Funds Weigh In On Outset Medical

A number of institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in Outset Medical by 955.9% during the second quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock worth $7,984,000 after acquiring an additional 376,196 shares in the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Outset Medical during the 2nd quarter worth about $78,000. Ensign Peak Advisors Inc raised its holdings in shares of Outset Medical by 272.4% in the 2nd quarter. Ensign Peak Advisors Inc now owns 314,522 shares of the company’s stock valued at $6,042,000 after purchasing an additional 230,065 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Outset Medical by 662.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 8,452 shares of the company’s stock valued at $162,000 after purchasing an additional 7,344 shares during the period. Finally, Legal & General Group Plc acquired a new stake in Outset Medical in the 2nd quarter valued at about $34,000.

Wall Street Analyst Weigh In

OM has been the topic of a number of research reports. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $7.00 price target on shares of Outset Medical in a research note on Wednesday, December 17th. BTIG Research decreased their price target on shares of Outset Medical from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Stifel Nicolaus lowered their price objective on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. Finally, Wall Street Zen downgraded shares of Outset Medical from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $10.00.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.